Divalent Chalcogen Or Acyclic Nitrogen Double Bonded Directly At Both 2- And 4- Positions, Or Tautomeric Equivalent (e.g., Hydantoin, Etc.) Patents (Class 514/389)
  • Patent number: 11147799
    Abstract: This disclosure relates to a pharmaceutical composition for topical use wherein the active pharmaceutical ingredient consists of the co-analgesic phenytoin and at least one further co-analgesic, and a method for producing the pharmaceutical composition. In addition, the disclosure relates to the pharmaceutical composition for use in the treatment of chronic pain.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: October 19, 2021
    Assignees: TOPICAL INNOVATIONS B.V.
    Inventors: David Jos Kopsky, Jan Marius Keppel Hesselink
  • Patent number: 11059790
    Abstract: The present disclosure relates to a compound that has biocidal activity or is a precursor of a compound with biocidal activity. The compound comprises an N-halamine precursor, at least one quaternary ammonium and at least one coating-incorporation group (CIG). In some embodiments of the present disclosure, the compound may be incorporated into a coating formulation. The coating formulation comprises the compound and at least one further component. In some embodiments of the present disclosure, the CIG reacts with the further component of the coating formulation to incorporate the compound into the coating formulation. In some embodiments, the coating formulation comprises a polymer. In some embodiments, the CIG of the compound reacts with the further component to incorporate the compound into the polymer of the coating formulation. The coating formulation may be used to coat a substrate. The coated substrate may demonstrate biocidal activity or the potential for increased biocidal activity.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: July 13, 2021
    Assignee: University of Manitoba
    Inventors: Zachary J. Wolff, Sadegh Ghanbar, Dominic Tessier, Chenxi Ning, Jonathan van Leeuwen, Marcelo Dubiel, Gurmeet Singh Bindra, Song Liu
  • Patent number: 11053227
    Abstract: Subject-matter of the present invention is a process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction of the corresponding beta-amino ketones. Subject-matter of the invention are also said novel synthesis intermediates and the use thereof in the preparation of active pharmaceutical ingredients, among which vilanterol and the salts thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 6, 2021
    Assignee: OLON S.P.A.
    Inventors: Corrado Colli, Giorgio Bertolini, Mara Sada, Faris Garis, Filippo Nisic, Aldo Bianchi, Cinzia Biaggi, Romano Di Fabio, Silvano Ronzoni, Stefania Bertuolo, Adolfo Prandi, Stefano Maiorana
  • Patent number: 11013810
    Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, ChiaTing Huang, John Mao
  • Patent number: 10919929
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: February 16, 2021
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
  • Patent number: 10821098
    Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: November 3, 2020
    Assignee: Lyotropic Therapeutics, Inc.
    Inventors: David Anderson, Benjamin G. Cameransi, Jr., Vincent M. Conklin
  • Patent number: 10670065
    Abstract: A toggle fixing for fixing an article to a thin-walled component, having a crosspiece for engaging behind the component, which crosspiece has an opening for receiving a screw. Connected to the crosspiece there is an elongated strip having a displaceable sleeve which has a screw hole for passage of the screw. The sleeve has an engagement element for threaded engagement of a screw in order that the latter does not unintentionally tilt the crosspiece during mounting. In order to provide quick insertion of a screw, the engagement element has a manipulating element such that the engagement element is movable radially outwards relative to the longitudinal axis, and the engagement element is manipulatable from a rear side of the sleeve emote from the crosspiece.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 2, 2020
    Assignee: fischerwerke GmbH & Co. KG
    Inventor: Aaron Daly
  • Patent number: 10596164
    Abstract: The present invention relates to compounds having a backbone structure for use as antibiotic, more specifically use against infections with Gram positive bacteria, preferably Clostridium, more preferably C. dfficile or C. perfringens. The compounds of the invention are particularly useful against spores of these bacteria.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 24, 2020
    Assignee: Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO
    Inventors: Frank Henri Johan Schuren, Roy Christiaan Montijn
  • Patent number: 10532102
    Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 14, 2020
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, ChiaTing Huang, John Mao
  • Patent number: 10314822
    Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 11, 2019
    Assignee: Lyotropic Therapeutics, Inc.
    Inventors: David Anderson, Benjamin G. Cameransi, Jr., Vincent M. Conklin
  • Patent number: 10292967
    Abstract: A composition for opththalmic administration comprising a formaldehyde releasing agent, sodium bicarbonate, and an ophthalmically suitable carrier or excipient is provided.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: May 21, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: David Choohyun Paik, Stephen Lewis Trokel
  • Patent number: 10149847
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: December 11, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Patent number: 10105305
    Abstract: The present invention relates to the field of wound healing. Specifically, the present invention provides compositions and methods for promoting skin regeneration, more specifically, the generation of de novo hair follicles. In one embodiment, a method for stimulating hair follicle neogenesis in a subject comprises the step of administering to the subject an effective amount of a TLR3 agonist. In certain embodiments, the TLR3 agonist is a double stranded RNA (dsRNA). The present invention is also directed to treating common male pattern hair loss.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 23, 2018
    Assignee: The Johns Hopkins University
    Inventors: Luis Andres Garza, Amanda Marie Nelson
  • Patent number: 9682960
    Abstract: Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 20, 2017
    Assignee: ENDORECHERCHE, INC.
    Inventors: Fernand Labrie, Shankar Mohan Singh, Richard Labrecque, Liviu Constantin Ciobanu
  • Patent number: 9169254
    Abstract: The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: October 27, 2015
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toru Esaki, Yoshikazu Nishimura, Yoshiaki Isshiki, Naoki Okamoto, Yoshiyuki Furuta, Akemi Mizutani, Masateru Ohta, Wayne Wen Lai, Tomoya Kotake
  • Patent number: 9044425
    Abstract: A method for the prevention or treatment of an eye disease, which includes topically applying to a patient in need of the treatment an aqueous ophthalmic composition which includes N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine, in combination with an amount of a cellulose compound or a pharmacologically acceptable salt which is effective to increase intraocular absorption of N-acetylcarnosine or L-carnosine or a derivative of L-carnosine, such as anserine or balenine, in the aqueous humor. A hydrophilic hydrogel contact lens and an ocular polymer insert for topical application of an ophthalmic composition to the eyes of a patient is also disclosed, with the lens or insert containing N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: June 2, 2015
    Inventor: Mark A. Babizhayev
  • Publication number: 20150148353
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Application
    Filed: June 28, 2013
    Publication date: May 28, 2015
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • Publication number: 20150132405
    Abstract: The present invention provides synergistic combinations of monochlorourea with other biocides for controlling microbial growth in aqueous systems. It also provides synergistic combinations of dimethyl monochlorourea with other biocides for controlling growth in aqueous systems. The synergistic combinations of monochlorourea and dimethyl monochlorourea with other biocides allows for the reduced use of total biocides to provide control of microbial growth in aqueous systems.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 14, 2015
    Applicant: HERCULES INCORPORATED
    Inventor: John S Chapman
  • Patent number: 9028853
    Abstract: A moisture-permeable glove or other garment protects against user contamination and cross-contamination by providing both rapid and persistent sterilization. Exposure to halogen of inherent NH groups and/or attached hydantoin can form a persistent outer halamine sterilization layer. A second inner halamine layer intercepts any pathogens that penetrate the outer surface. The garment can be single layer, or can include a detachable inner liner. Embodiments are compatible with rapid decontamination using an alcohol-based agent. Some embodiments provide a 180 second 3-log kill rate for at least S. aureus ATCC and E. coli. Embodiments include a moistening agent to activate the halamine. An anti-cut/puncture layer and/or a pathogen barrier layer can also be included. The protective layer can include contiguous layers of soft and hard metal flexed to improve flexibility and Moisture Vapor Transport Rate (MVTR). The pathogen barrier can include urethane and/or CNT fibers. The garment MVTR can be greater than 0.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: May 12, 2015
    Assignee: Warwick Mills Inc.
    Inventor: Charles A. Howland
  • Publication number: 20150126435
    Abstract: Disclosed are primers, probes, and single nucleotide polymorphisms (SNP) specific to a distinct subclones of the E. coli sequence type 131 (ST131). Also disclosed are methods and assay kits useful in detecting the presence of the distinct subtype of E. coli and methods of treating a subject suffering from an infection from a subclone of ST131.
    Type: Application
    Filed: July 2, 2013
    Publication date: May 7, 2015
    Inventors: Lance B. Price, Evgueni V. Sokurenko, James R. Johnson
  • Patent number: 9023879
    Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Medivation Prostate Therapeutics, Inc.
    Inventors: Rajendra Parasmal Jain, Jacqueline A. Gibbons
  • Patent number: 9018239
    Abstract: In the growing of crops for consumption, a method for the removal of pathogens includes the addition to irrigation water for the crops of an anti-pathogen composition and supplying the anti-pathogen composition to the crops prior to harvest while normal irrigation is effected. The anti-pathogen composition is based on halogens, such as chlorine, bromine and iodine, or mixtures of halogens or halogens combined with other organic radicals including cyanurate, hydantoin, peroxide and chlorine dioxide. BCDMH and TICA are preferred anti-pathogen components of the anti-pathogen composition and may be added to a carrier concentrate and measured and dosed into the irrigation water.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: April 28, 2015
    Inventors: William Bliss, Sandra Bliss
  • Publication number: 20150073004
    Abstract: The present invention relates to compounds of formula 1 that are useful for the preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Inventors: Imre BATA, Veronika BARTONE BODOR, Attila VASAS, Peter BUZDER-LANTOS, Gyorgy FERENCZY, Zsuzsanna TOMOSKOZI, Gabor SZELECZKY, Zsuzsanna SZAMOSVOLGYI
  • Patent number: 8975284
    Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 10, 2015
    Assignee: US WorldMeds LLC
    Inventors: Ahmad Malkawi, Abeer M. Al-Ghananeem, Patrick DeLuca, George A. Digenis
  • Publication number: 20150057323
    Abstract: The composition for treating ocular effects of diabetes is a composition that contains an aldose reductase inhibitor in an ophthalmic gel for topical application to the eye. The composition includes a carrier having, by weight, about 0.4% carbomer, 4.0% sorbitol, 0.01% centrimide, 0.01% ethylenediaminetetraacetic acid (EDTA) and effective amounts of sodium chloride and sodium hydroxide for adjusting the pH of the topical carrier to about 7 and to achieve a desired viscosity, with the balance being water. The aldose reductase inhibitor (ARI) is mixed with the topical carrier at about 0.1%-6% by weight of the composition to form an ophthalmic gel. Preferably, the ARI is 2R,4S-6-fluoro-2-methyl-spiro[chroman-4,4?-imidazolidine]-2?,5?-dione, referred to as 2-methyl sorbinil, having the structure: or a pharmaceutically acceptable salt thereof. In use, the ophthalmic gel is preferably applied as an eye drop at a dosage of one drop per eye administered two to three times daily.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 26, 2015
    Applicant: THERAPEUTIC VISION, INC.
    Inventors: MILTON WYMAN, VINCENT BELLAVIA
  • Patent number: 8957083
    Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A1, A3, A4, A5, A6, A8, L, R2, R7, R9, W and Y of Formula I are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, sub-Formula embodiments of Formulas I, II and III, intermediates and processes and methods useful for the preparation of compounds of Formulae I-III.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: February 17, 2015
    Assignee: Amgen Inc.
    Inventors: Ana Elena Minatti, Oleg Epstein, Ryan White, Matthew Weiss, Wenge Zhong, Jonathan D. Low
  • Publication number: 20140371692
    Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.
    Type: Application
    Filed: April 29, 2014
    Publication date: December 18, 2014
    Applicants: A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS RUSSIAN ACADEMY OF SCIENCES, CORIUM INTERNATIONAL, INC.
    Inventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platè, Valery G. Kulichikhin
  • Patent number: 8894986
    Abstract: A monomeric adhesive composition includes a stabilized polymerizable monomer, such as a 1,1-disubstituted monomer, including a cyanoacrylate, and a wound healing agent, wherein the wound healing agent is 5,5-disubstitutedhydantoin, including phenytoin; and a method for making said composition.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: November 25, 2014
    Assignee: Adhezion Biomedical, LLC
    Inventors: Sheng Zhang, Rafael Ruiz, Sr.
  • Patent number: 8895036
    Abstract: The invention relates to transdermal compositions including nifedipine, pentoxifylline, ketamine hydrochloride, gabapentin, lidocaine, and prilocaine that may be used to treat conditions such as circulatory disorders and peripheral neuropathy. Additionally, methods of the invention are directed to treating conditions such as circulatory disorders, peripheral neuropathy, wound healing, blood flow issues, or the like, comprising the steps of transdermal or topical administration of the compositions.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: November 25, 2014
    Assignee: JCDS Holdings, LLC
    Inventor: Jay Richard Ray, II
  • Publication number: 20140319059
    Abstract: Provided herein is a method for reducing down-time in a recreational body of water having a water filtering system and water recirculation system after a potential release of Cryptospridium oocyst and/or Giardia cysts. Also described is a kit for practicing the method for reducing down-time in a recreational body of water that may have a potential release of Cryptospridium oocyst and/or Giardia cysts.
    Type: Application
    Filed: April 25, 2014
    Publication date: October 30, 2014
    Inventor: Michael Joseph Unhoch
  • Patent number: 8859529
    Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 14, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Ling Tong, Michael K. C. Wong, Brian J. Lavey, Joseph A. Kozlowski, Lei Chen, Razia K. Rizvi, Aneta Maria Kosinski, De-Yi Yang, Guowei Zhou, Kristen E. Rosner, Luke Fire, Judson E. Richard, Dansu Li
  • Publication number: 20140288106
    Abstract: The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 25, 2014
    Applicant: Sanofi
    Inventors: Imre BATA, Peter BUZDER-LANTOS, Attila VASAS, Veronika BARTANE BODOR, Gyorgy FERENCZY, Zsuzsanna TOMOSKOZI, Gabor SZELECZKY, Sandor BATORI, Martin SMRCINA, Marcel PATEK, Aleksandra WEICHSEL, David Squire Thorpe
  • Publication number: 20140235649
    Abstract: A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor.
    Type: Application
    Filed: May 24, 2012
    Publication date: August 21, 2014
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. Kovach, Zhengping Zhuang, Jie Lu, Chunzhang Yang, Russell Lonser
  • Publication number: 20140206693
    Abstract: Certain embodiments are directed to methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway using an aldose reductase specific inhibitor.
    Type: Application
    Filed: January 27, 2014
    Publication date: July 24, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Satish K Srivastava, Kota V Ramana
  • Publication number: 20140200223
    Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
    Type: Application
    Filed: December 18, 2013
    Publication date: July 17, 2014
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian Mckeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
  • Patent number: 8765757
    Abstract: The present invention relates to 3-Heterocyclic Substituted Indole Derivatives, compositions comprising at least one 3-Heterocyclic Substituted Indole Derivative, and methods of using the 3-Heterocyclic Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: July 1, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tin-Yau Chan, Jose S. Duca, Liwu Hong, Charles A. Lesburg, Brian A. McKittrick, Haiyan Pu, Li Wang, Henry M. Vaccaro
  • Patent number: 8759384
    Abstract: Compounds represented by Formula I and II, or pharmaceutically acceptable salts thereof: inhibit bacterial 2-epimerase and are useful anti-infective agents.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: June 24, 2014
    Inventors: David J. Bearss, Hariprasad Vankayalapati, Yong Xu, Charles Erec Stabbins, Vincent A. Fischetti
  • Publication number: 20140147691
    Abstract: The present invention relates to a preservative formulation for use in treating wood or other cellulosic materials, said formulation comprising: at least one biocidal metal compound; at least one preservative; and an aqueous carrier, wherein the preservative formulation has an uptake in the sapwood of less than about 220 l/m3 yet achieves substantially full penetration of the sapwood. Preferably, the preservative formulation is copper/tebuconazole in a ratio of about 25/1 w/w; and the wood is around 25 mm in thickness—for instance, decking timber.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 29, 2014
    Applicant: ARCH WOOD PROTECTION PTY LTD
    Inventors: David Humphrey, Brett Skewes, Angelo Hrastov, Drago Bagaric, Peter Hausler, Shane McFarling, Greg Jensen, Steve Koch, Noel Koskela, Troy Justice
  • Publication number: 20140147448
    Abstract: The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased cardiovascular risk.
    Type: Application
    Filed: June 5, 2012
    Publication date: May 29, 2014
    Applicant: Yale University
    Inventors: John Hwa, WaiHo Tang
  • Publication number: 20140137808
    Abstract: The present invention is directed to an insect repelling device that may serve as an effective barrier against ticks. The insect repelling device may include a band of technical fabric, with the fabric being very stretchable. The insect repelling device may be worn around the ankles, wrist or head. The insect repelling device may be worn in pairs on each ankle and/or wrist. The insect repelling device may have an open, tubular design and be made of a high performance, nylon/ polyester fabric, allowing a user to easily insert the foot or hand and fit the device around the ankle or wrist area. Each insect repelling device may be pre-treated with an insecticide or insect repellant, such as Permethrin. In use, the insect repellant device may be effective at preventing biting insects, such as ticks, from crawling onto the user, for example from crawling up the legs of the user.
    Type: Application
    Filed: March 6, 2013
    Publication date: May 22, 2014
    Inventor: Simon J. WHITE
  • Patent number: 8729096
    Abstract: The present invention relates to novel imidazolidine-2,4-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2 (FPR2).
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 20, 2014
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Vidyasagar Vuligonda, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8710091
    Abstract: The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R1, R2, R3, R4, X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The invention also relates to pharmaceutical compositions containing said materials and to the use thereof for preparing a drug.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: April 29, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Grégorie Prevost, Serge Auvin, Christophe Lanco, Anne-Marie Liberatore, Olivier Lavergne
  • Publication number: 20140099512
    Abstract: A roofing and/or siding material that reduces the incidence of undesired micro-organisms from entering into the air intake of air conditioner and/or heating systems of a building structure to thereby improve the quality of the air in the building structure.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 10, 2014
    Applicant: Garland Industries, Inc.
    Inventors: David Sokol, Jason Smith
  • Patent number: 8685460
    Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: April 1, 2014
    Assignee: Lyotropic Therapeutics, INc
    Inventors: David Anderson, Benjamin G. Cameransi, Jr., Vincent M. Conklin
  • Publication number: 20140088112
    Abstract: The present invention is directed to alkyne benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Scott D. Kuduk, Jason W. Skudlarek
  • Publication number: 20140088150
    Abstract: The present invention is directed to cyclohexene benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Douglas C. Beshore, Scott D. Kuduk
  • Publication number: 20140073639
    Abstract: The application describes targets and methods that can inhibit bacterial growth in Gram-positive and Gram-negative bacteria. A bacterial enzyme, 2-epimerase, is common to both Gram-positive and Gram-negative bacteria and contains an allosteric site that can be targeted to disrupt the enzyme. The allosteric site is present on the bacterial 2-epimerase, but the analogous mammalian enzyme does not contain the allosteric site, providing a route for attacking bacterial infections without affecting the mammalian enzyme.
    Type: Application
    Filed: August 8, 2013
    Publication date: March 13, 2014
    Applicants: The Rockefeller University, Avacyn Pharmaceuticals, Inc.
    Inventors: Vincent A. FISCHETTI, Allan R. GOLDBERG, Raymond SCHUCH
  • Publication number: 20140073611
    Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 13, 2014
    Applicant: National Taiwan University
    Inventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
  • Publication number: 20140066466
    Abstract: Described herein are compositions that inhibit the production of TNF? downstream of CD40 activation. As such, also described are various methods of using compositions exhibiting this activity for the treatment or prevention of inflammatory diseases associated with TNF? production or CD40 activation.
    Type: Application
    Filed: March 12, 2012
    Publication date: March 6, 2014
    Applicant: President and Fellows of Harvard College
    Inventor: Junying Yuan
  • Publication number: 20140066443
    Abstract: The present invention is directed to aminomethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 6, 2014
    Inventors: Douglas C. Beshore, Robert M. Garbaccio, Scott D. Kuduk, Adam W. Johnson, Jason W. Skudlarek